


ALX-1393 TFA

Cat. No.:	HY-111029A
Molecular Formula:	C ₂₅ H ₂₃ F ₄ NO ₆
Molecular Weight:	509.45
Target:	GlyT
Pathway:	Membrane Transporter/Ion Channel; Neuronal Signaling
Storage:	-20°C, sealed storage, away from moisture * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)



SOLVENT & SOLUBILITY

In Vitro

DMSO : 100 mg/mL (196.29 mM; ultrasonic and warming and heat to 60°C)

Solvent	Mass	Concentration		
		1 mg	5 mg	10 mg
Preparing Stock Solutions	1 mM	1.9629 mL	9.8145 mL	19.6290 mL
	5 mM	0.3926 mL	1.9629 mL	3.9258 mL
	10 mM	0.1963 mL	0.9815 mL	1.9629 mL

Please refer to the solubility information to select the appropriate solvent.

BIOLOGICAL ACTIVITY

Description

ALX-1393 TFA, a selective GlyT2 inhibitor, has an antinociceptive effect on thermal, mechanical, and chemical stimulations in a rat acute pain model^[1].

In Vitro

ALX1393 TFA (i.c.v.; 25, 50, and 100 µg) in normal rats suppresses the late-phase response in the formalin test but does not affect motor performance. ALX1393 inhibits mechanical and cold hyperalgesia in a dose-dependent manner^[2].
MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. Haranishi Y, et al. The antinociceptive effect of intrathecal administration of glycine transporter-2 inhibitor ALX1393 in a rat acute pain model. *Anesth Analg*. 2010 Feb 1;110(2):615-21.

[2]. Takahashi Y, et al. Antinociceptive effect of intracerebroventricular administration of glycine transporter-2 inhibitor ALX1393 in rat models of inflammatory and neuropathic pain. *Pharmacol Biochem Behav*. 2015 Mar;130:46-52.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA